Silence Therapeutics

Company snapshot

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to pot

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Silence Therapeutics. Not investment advice.

• Peer + 0 momentum

  Esperion Therapeutics

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Silence Therapeutics.

1. Jun 8, 2026 Clinical update

   SLN124-001 — Phase 1

2. Jun 5, 2026 Clinical update

   SLN124 — Phase 1

3. May 23, 2026 Clinical update

   Atu027 & gemcitabine in lead in safety period — Phase 2

4. May 23, 2026 Clinical update

   SLN124 — Phase 2

5. May 23, 2026 Clinical update

   SLN360 — Phase 2

View all clinical trial activity →

• What is Silence Therapeutics?

  Silence Therapeutics is a pharma organization headquartered in London, GB. It trades on NYSE under ticker SLN. Primary therapeutic focus areas include Non-transfusion-dependent Thalassemia, Advanced Solid Tumors, Carcinoma, Pancreatic Ductal, Polycythemia Vera, Cardiovascular Dis

• Is Silence Therapeutics publicly traded?

  Yes. Silence Therapeutics is listed with ticker SLN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Silence Therapeutics develop or market?

  We link 6 drug profile(s) where Silence Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/silence-therapeutics-plc#company-drugs.

• What are the latest developments for Silence Therapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Silence Therapeutics focus on?

  Silence Therapeutics focuses on Non-transfusion-dependent Thalassemia, Advanced Solid Tumors, Carcinoma, Pancreatic Ductal based on our analysis of their pipeline programs and drug development activities.